On Thursday, Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s shares declined -2.88% to $3.04.
Idera Pharmaceuticals Inc (IDRA) declared the achievement of key development milestones for its product candidate IMO-9200, an antagonist of Toll-like receptors (TLRs) 7, 8 and 9. Specifically, the company recently stated top-line data from a Phase 1 clinical trial of IMO-9200 in healthy subjects and declared the presentation of new preclinical data for IMO-9200 in models of inflammatory bowel disease (IBD) at the 2015 Digestive Disease Week Conference (DDW) in Washington, DC.
In the placebo-controlled Phase 1 clinical trial in 30 healthy subjects, IMO-9200 was administered by subcutaneous injection at escalating single-dose levels of 0.1, 0.3, and 0.5 mg/kg. In the multiple dose cohort, a dose of 0.5 mg/kg/week for four weeks was also evaluated. All dose regimens were well tolerated, with no serious adverse events related to IMO-9200 treatment stated. There were no patterns of laboratory or other safety parameters suggestive of any related adverse treatment effect.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, counting toll-like receptor targeting technology and gene silencing oligonucleotide (GSO) technology.
Plains All American Pipeline, L.P. (NYSE:PAA)’s shares dropped -2.66% to $47.56.
Plains All American Pipeline, L.P. (PAA) and Plains GP Holdings (NYSE: PAGP) recently stated first-quarter 2015 results.
First-quarter 2015 Transportation adjusted segment profit raised 15% as compared to comparable 2014 results. This enhance was primarily driven by higher crude oil pipeline volumes associated with recently accomplished organic growth projects and earnings from our 50% interest in the BridgeTex pipeline. In addition, certain of our Canadian terminals were reclassified from the Facilities segment to the Transportation segment in the second quarter of 2014.
First-quarter 2015 Facilities adjusted segment profit exceeded the high end of our quarterly guidance range but reduced by 9% over comparable 2014 results. This decrease was primarily due to lower revenues from our rail terminals due to lower fees related to the movement of certain volumes of Bakken crude oil, unfavorable foreign currency impacts on Canadian natural gas liquids (“NGL”) activities and the reclassification of certain Canadian terminals to the Transportation segment.
First-quarter 2015 Supply and Logistics adjusted segment profit raised by 19% over comparable 2014 results. This enhance was primarily driven by favorable NGL market conditions, offset partially by crude oil differentials that were not as favorable in 2015 as they were in 2014. Additionally, 2014’s first quarter results comprised of costs to manage deliverability requirements associated with our natural gas storage activities, which were not incurred in the current year period.
Plains All American Pipeline, L.P., through with its auxiliaries, engages in the transportation, storage, terminal ling, and marketing of crude oil, natural gas liquids (NGL), natural gas, and refined products in the United States and Canada. The company operates in three segments: Transportation, Facilities, and Supply and Logistics.
At the end of Thursday’s trade, Tekmira Pharmaceuticals Corp (NASDAQ:TKMR)‘s shares dipped -2.53% to $13.89.
Tekmira Pharmaceuticals Corp (TKMR) declared that Dr. Mark Murray, Tekmira’s President and CEO, will present a corporate update at the Jefferies 2015 Healthcare Conference on Tuesday, June 2, 2015 at 12.30pm — 1.00pm (PT) / 3.30pm-4.00pm (ET) in New York.
Tekmira Pharmaceuticals Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics; and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada.
FibroGen Inc (NASDAQ:FGEN), ended its Thursday’s trading session with -2.50% loss, and closed at $17.55.
FibroGen Inc (FGEN) declared that it has received a $15 million milestone payment from AstraZeneca AB (“AstraZeneca”), triggered by the completion of roxadustat non-clinical carcinogenicity studies. In two separate two-year carcinogenicity studies, in rats and in mice, there was no evidence of a roxadustat-related effect on mortality or carcinogenicity.
Non-clinical carcinogenicity data are a standard component of novel small molecule drug development and are typically required by the U.S. Food and Drug Administration and other regulatory agencies as part of the drug approval process.
Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that acts by stimulating the body’s natural pathway of red blood cell production, or erythropoiesis. Roxadustat is the first HIF-PHI to enter Phase 3 clinical development and represents a novel approach to the treatment of anemia in patients with chronic kidney disease (CKD), with the potential to address the considerable unmet medical need for an effective treatment for anemia that offers the convenience of oral administration and an improved safety profile as contrast to current standards of care.
FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
